Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3cc6401a2c9fd975eec083bd4acc3f6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b99e2c723498fb91a5f3957b9560a17a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef197df54d4509a199bee16bb4e63331 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90dc31127e33e0ae677059b9fad7c961 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
filingDate |
2019-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2021-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c01db8649f71067efe575f7f1202f8ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c82da6a5c1293df4e31ad93b26fee44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53c394741333b460c60376afc0d324c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55840e41bb2172f9c2c58fb7378c3504 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2b3841e3ac41f601b4cff5ada5263bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c3af7cedf67a1ed2b5fe671f24d0fc9 |
publicationDate |
2021-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11045558-B2 |
titleOfInvention |
RPGR gene therapy for retinitis pigmentosa |
abstract |
Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA. |
priorityDate |
2014-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |